|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | SEC 1473 (7-02) | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | |||
| 1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
| Feng Dai C/O CBPO JIALONG INT'L TOWER, CHAO YANG PARK RD. BEIJING, F4 100125 |
 X |  |  |  |
| /s/ Feng Dai | 05/09/2014 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | This Form 3 is being filed in connection with the appointment of Mr. Dai Feng (the "Reporting Person" or "Mr. Feng") as a Director of China Biologic Products, Inc. (the "Issuer") on May 4, 2014. |
| (2) | The 10,989,200 shares of common stock, $0.0001 par value per share ("Common Stock") of the Issuer are held by WP X Biologics LLC, a Delaware limited liability company ("WP X B"), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X") and holder of 96.9% of the equity interest in WP X B, and Warburg Pincus X Partners, L.P., a Delaware limited partnership and holder of 3.1% of the equity interest in WP X B ("WPP X", and together with WP X, the "WP X Funds"). Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP"), is the general partner of the WP X Funds. (continued on footnote 3) |
| (3) | Warburg Pincus X LLC, a Delaware limited liability company ("WP X LLC"), is the general partner of WP X LP. Warburg Pincus Partners LLC, a New York limited liability company ("WP Partners"), is the sole member of WP X LLC. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WP Partners. Warburg Pincus LLC, a New York limited liability company ("WP LLC"), is the manager of the WP X Funds. |
| (4) | Mr. Feng is a Managing Director of WP LLC. As such, Mr. Feng may be deemed to have an indirect pecuniary interest (within the meaning of Rule 16a-1 under the Securities and Exchange Act of 1934, as amended (the "Exchange Act")) in an indeterminate portion of the securities reported as beneficially owned by the WP X Funds. Mr. Feng disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Mr. Feng does not directly own any shares of Common Stock of the Issuer. |
|  Remarks: This Form 3 shall not be deemed an admission that the Reporting Person or any other person referred to herein is a beneficial owner of the shares of Common Stock held by the WP X Funds for purposes of Section 16 of the Exchange Act or for any other purpose. | |